Chemotherapy for Neuroendocrine Tumours
Author Information
Author(s): Mitry E, Baudin E, Ducreux M, Sabourin J-C, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P
Primary Institution: Institut Gustave Roussy, Villejuif, France
Hypothesis
The study aims to evaluate the efficacy of a chemotherapy regimen combining etoposide and cisplatin in treating neuroendocrine tumours.
Conclusion
The study confirms that poorly differentiated neuroendocrine tumours respond to etoposide and cisplatin, but the prognosis remains poor.
Supporting Evidence
- 41 patients with poorly differentiated tumours had an objective response rate of 41.5%.
- The median duration of response was 9.2 months.
- The median overall survival was 15 months.
- The median progression-free survival was 8.9 months.
- 60% of patients experienced haematological grade 3–4 toxicity.
Takeaway
This study looked at how well a specific cancer treatment works for patients with a certain type of cancer, and found that while it can help some, many still do not survive long.
Methodology
Retrospective analysis of 53 patients treated with etoposide and cisplatin.
Limitations
The prognosis for patients remains poor despite treatment.
Participant Demographics
12 patients had well-differentiated tumours and 41 had poorly differentiated tumours.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website